contacting Stephen Finley, Ph.D., at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852–3804 (telephone 301/496–7735, ext. 215; fax 301/402–0220). A signed Confidential Disclosure Agreement will be required to receive a copy of the patent applications.

A Method for Imaging Nicotinic Acetylcholinergic Receptors in the Brain Using Radiolabeled Pyridyl 7-Azabicycloheptanes

ED London, AS Kimes, A Horti, RF Dannals, M Kassiou (NIDA) Serial No. 08/642,636 filed 06 May 96

The current invention embodies the use of radiolabeled analogs of epibatidine to noninvasively image and quantify levels of nicotinic acetylcholine receptors in a living mammalian brain, using Positron Emission Tomography or other nuclear medicine methods. As nicotinic acetylcholine receptors have been implicated in various neuropathological and physiological disorders, including Alzheimer's disease, the invention may represent a powerful new method for the noninvasive diagnosis of Alzheimer's disease and other disorders. In addition, the method embodied in the invention may prove valuable for use in monitoring the progression of various disorders and in determining the efficacy of drug therapy protocols used in the treatment of these disorders. (portfolio: Central Nervous System—Diagnostics, in vivo)

Identification of an Allelic Ser_{857}–Asn_{857} Variation of the Human Delayed Rectifier Potassium Channel DRK1 (KCNB1 locus)

D Goldman, AW Bergen, CM Mazzanti, S Michelini (NIAAA) Serial No. 60/020,348 filed 24 Jun 96

The DRK1 potassium channel is voltage sensitive such that as phosphorylation of the protein is increased the current is reduced, thereby increasing the cell's excitability. The amino- and carboxyl-terminal regions of DRK1 are located in the cytoplasm. A new, but naturally occurring substitution of the human delayed rectifier potassium channel DRK1 (KCNB1 locus) was mapped to chromosome 20q13.2. The nonconservative substitution occurs at position 857 in the carboxy terminal region of the protein. Transmembrane sequences of the rat and human DRK1 have been shown elsewhere to be identical, but have different pharmacological and conductance differences. The substitution of cytoplasmic serine to asparagine may effectively remove a possible phosphorylation site which could result in increased excitability of the cell or effect the function of the protein by altering the conformation, thereby accounting for the pharmacological and conductance changes. The DRK1 was mapped to the same locus as the dominantly inherited EEG trait difference, a low voltage alpha trait difference (20q13.3–13.3), but no correlation could be found between the substitution and the low voltage alpha trait. (portfolios: Central Nervous System—Therapeutics, psychotherapeutics; Central Nervous System—Diagnostics; Central Nervous System—Research Materials).

Dated: October 28, 1996.

Barbara M. McGarey,

Deputy Director, Office of Technology Transfer.

[FR Doc. 96–28274 Filed 11–1–96; 8:45 am]

BILLING CODE 4140–01–M

National Cancer Institute; Notice of Meeting

Notice is hereby given of the meeting of the National Cancer Institute Board of Scientific Advisors Clinical Trials Review Working Group, November 25–26, 1996 at the Doubletree Hotel, Rockville, Maryland.

The meeting will be open to the public on November 25, 1996 from 8 am to 2 pm for discussions of methods to maximize the exchange of information and collaboration between laboratory and clinical scientists and between the pharmaceutical industry and NCI funded researchers, and on November 26 from 8 am to 8:30 am for introductory remarks and welcome.

The meeting will be closed to the public on November 25, 1996 from 2 pm to approximately 6 pm and on November 26 from 8:30 am to approximately 6 pm for discussion of confidential issues relating to the review, discussion and evaluation of individual programs and projects conducted by the Clinical Trials Extramural Program. These discussions will reveal confidential trade secrets or commercial property such as patentable material, and personal information including consideration of personnel qualifications and performance, the competence of individual investigators and similar matters, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Information pertaining to the meeting may be obtained from Dr. John S. Cole, III, Executive Secretary, National Cancer Institute Clinical Trials Review Working Group, National Cancer Institute, 6130 Executive Blvd., EPN, Rm. 540, Bethesda, MD 20892 (301–496–1718).

Individuals who plan to attend and need special assistance such as sign language interpretation or other reasonable accommodations should contact Dr. Cole in advance of the meeting.

Dated: October 28, 1996.

Paula N. Hayes,

Acting Committee Management Officer, NIH.

[FR Doc. 96–28266 Filed 11–1–96; 8:45 am]

BILLING CODE 4101–01–M

National Cancer Institute; Notice of Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting of the National Cancer Institute Frederick Cancer Research and Development Center Advisory Committee.

The open portion of the meeting will be limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the contact person in advance of the meeting.

Committee Name: Frederick Cancer Research and Development Center Advisory Committee.

Date: December 17–18, 1996.

Place: Frederick Cancer Research and Development Center, Building 549, Executive Board Room.

Open: December 17—8:30 a.m.–11:00 a.m.

Agenda: Discussion of administrative matters such as future meetings, budget, and information items related to the operation of the NCI Frederick Cancer Research and Development Center.

Closed: December 17—11 a.m. to 5:00 p.m. December 18—8:30 a.m. to 5:00 p.m.

Agenda/Purpose: Discussion of previous site visit report and response for the Core Support Services with Science Applications International Corporation. The majority of the closed session will be devoted to a site review of the Molecular Virology and Carcinogenesis Laboratory under contract with ABL-Basic Research.

Contact Person: Cedric W. Long, Ph.D., Frederic Cancer Research and Development Center, P.O. Box B, Frederick, MD 21702, Telephone: 301–846–1108.

The meeting will be closed in accordance with the provisions set forth in secs. 552b(2)(4) and 552b(c)(6), Title 5 U.S.C. The report and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the programs, disclosure of